Retatrutide
Weight Loss.
Engine Reset.
Fat Detox.
■ Metabolic "Engine Reset"
■ Up to 24% Body Weight Loss
■ Premium Quality w/99% Purity
■ GLP-1 + GIP + Glucagon Agonist
■ Preserve Muscle Mass
■ Blood Sugar Regulation
■ Less Food Cravings
■ Reduce Inflammation & Bloat
■ Transform in 3-9 Months
Text 469-894-3400
NEW ORAL VERSION OR TRADITIONAL INJECTABLE
Lose 20-50 lbs in 3-8 Months
Lose 5-15 lbs = "10mg or "Starter"
Lose 20-40 lbs = "Reta Deal/ 4 Mo/Lose 25lbs/ Launch or 3x 15mg" (select these to achieve your goal)
Lose 40-80 lbs = Start with 10mg or 15mg or the "Reta Launch" package and graduate to 20mg over time
SAVE 30% WITH A 3 MONTH COMMITMENT TO YOURSELF. AFTER PAY AVAILABLE.
Retatrutide (The Metabolic "Engine Overhaul")
This is the most powerful compound in 2026 for treating Metaflammation (chronic inflammation caused by excess fat and high blood sugar). It's primary power is to resolve "visceral" inflammation by rapidly reducing liver fat and clearing metabolic waste. Retatrutide has a unique molecular structure that potently activates three receptors (GLP-1, GIP, and glucagon), which can lead to the most significant weight reduction.
GLP 1: Semaglutide GLP-1 Agonist up to 10-15% of body weight
GLP 2: Tirzepatide GLP-1 + GIP Agonist with up to 15-20% of body weight loss
GLP 3: Retatrutide GLP-1 + GIP + Glucagon Agonist with up to 24% of body weight loss
Beyond Weight Loss: Retatrutide's Additional Benefits
• Helps with Inflammation: Retatrutide can reduce inflammation in various chronic conditions by reducing pro-inflammatory cytokines.
• Preserves Muscle Mass: While promoting significant fat loss, Retatrutide's multi-faceted approach is designed to help preserve muscle mass.
• Supports Overall Health: It also supports improvements in blood sugar regulation, insulin sensitivity, and energy metabolism.
Charlie T.
"What a game changer. Lost 45lbs and feel amazing. It is like hitting a reset button."
180 Day Member
Frank S.
"In week 3 I felt the shift. After that I lost 2 lbs a week. I cannot believe it! I'm 25 lbs and counting."
Elite Customer
Paula A.
"Started in December and lost 15 lbs by February. I feel so much better and I got more energy too."
90 Day Member
Susan C.
"Been on Reta for 2 months and I nearly hit my goal weight. I dropped serveral pant sizes!"
Elite Customer
Retatrutide's Unique Advantage
Retatrutide, a novel triple-agonist peptide (GLP-1, GIP, and glucagon) that primarily targets metabolic-driven inflammation.
Metabolic Inflammation: Lowers systemic inflammatory markers and cytokines associated with obesity and type 2 diabetes.
Liver Fat Reduction: Significantly reduces liver fat (up to 85% in trials), addressing the inflammation underlying metabolic dysfunction-associated steatotic liver disease (MASLD).
Joint Pain Relief: Phase 3 trials in early 2026 showed significant relief in knee osteoarthritis pain, likely due to reduced adiposity-related inflammation.
Cardiovascular Protection: Improves cardiometabolic markers such as blood pressure and triglycerides.
All GLPs are a once a week injection. Potential FDA approval in 2027.
Tirzepatide and Semaglutide have longer-standing clinical trials, but require a muscle protocol.
Reset Engine.
Lose Weight.
When Will I See Results?
In clinical trials, Retatrutide results follow a progressive timeline, with internal biological changes starting almost immediately, while physical will take a few weeks to show.
Hours to Days 1–3: Initial appetite suppression usually begins within 24 to 72 hours of the first injection. Participants often report a "silent snack zone" where the impulse to graze or cravings for sweets noticeably decrease.
Weeks 1–4: Early weight loss is typically 2% to 5% of body weight, largely due to reduced portion sizes and initial water weight loss. You may start feeling full sooner during meals. Most people notice a big shift in week 3.
Weeks 4–8: Pounds are dropping. Eat right and you will achieve your goal quicker. Focus on lots of water, protein.
Weeks 8–12: Measurable physical changes often emerge. You may notice clothing fitting looser and a reduction in facial puffiness. In trials, participants often reached 5% to 10% weight loss by this stage.
Months 6–12: This is the "significant transformation phase". In Phase 2 trials, participants on the highest dose achieved an average weight reduction of 17.5% at 24 weeks and reached 24.2% by 48 weeks.
Month 12–16: Peak results are typically seen by week 48 to 68. Long-term Phase 3 data (TRIUMPH-4) reported average losses as high as 28.7% (roughly 71 lbs) over 68 weeks for those on the highest doses.
Metabolic & Health Marker Results
Beyond weight loss, Retatrutide shows rapid impact on other health markers:
Blood Sugar: Significant drops in HbA1c (1.3 to 2.0 percentage points) occur as early as 24 weeks, with many participants achieving normoglycemia.
Liver Fat: In specialized studies, some participants saw an 80%+ reduction in liver fat by week 24.
Joint Pain: Improvements in mobility and relief from osteoarthritis-related knee pain are common milestones between months 9 and 16.
Note: These results are based on clinical study averages and may vary depending on individual biology, dose escalation, and lifestyle.
Build Muscle.
During your weight loss journey you have a unique opportunity to speed up your fat loss.
Retatrutide FAQs
What are the benefits?
GLP-1 (Glucagon-like peptide-1): Reduces appetite and slows stomach emptying, increasing satiety.
GIP (Gastric inhibitory polypeptide): Enhances fat metabolism and improves insulin response.
Glucagon (GCG): Increases energy expenditure (calorie burning).
Key Metabolic Effects:
Appetite Suppression: It significantly lowers food cravings and hunger.
Increased Metabolism: Activating the glucagon receptor, it forces the body to burn more energy, even at rest.
Fat Reduction: It promotes the breakdown of stored fat rather than just suppressing hunger.
Results & Administration: Administered as a weekly injection, participants are losing up to 24% of their body weight after 48 weeks. It is currently in Phase 3 trials and is designed to improve glycemic control and reduce fat.
What is Retatrutide
Retatrutide (LY3437943) is a research peptide, once-weekly injectable medication developed by Eli Lilly for treating obesity and type 2 diabetes, often called a "triple-G" agonist.. It acts on three receptors—GLP-1, GIP, and glucagon—to significantly reduce appetite, manage blood sugar, and enhance fat burning. It is currently in Phase 3 trials, with potential approval expected around 2026.
Key Details About Retatrutide:
Triple-Action Mechanism: Unlike semaglutide (Wegovy) or tirzepatide (Mounjaro), which target one or two receptors, retatrutide stimulates three: GLP-1, GIP, and glucagon.
High Weight Loss Potential: In clinical trials, it has shown high effectiveness, with some participants experiencing an average weight reduction of up to 24%.
Status: It is not yet FDA-approved and is currently undergoing Phase 3 clinical trials.
Side Effects: Similar to other GLP-1 medications, potential side effects include nausea, diarrhea, and stomach pain but overall severely less than Semaglutide and Tirzepatide.
Difference from Other Weight Loss Drugs:
Retatrutide is considered a next-generation weight loss therapy. It goes beyond the dual-action of tirzepatide by adding the glucagon component, which is believed to help increase energy expenditure in addition to suppressing appetite. It is being studied for its potential to produce more significant weight loss results than currently approved medications
How does the Retatrutide work?
Retatrutide is a "triple-agonist" weight-loss medication that mimics three hunger-regulating hormones—GLP-1, GIP, and glucagon (GCG)—to significantly reduce appetite, slow digestion, and increase calorie burning. By acting on these three receptors, it promotes substantial fat loss while potentially preserving muscle mass.
Triple Hormone Action (The "Triple G"): Unlike Wegovy (GLP-1 only) or Mounjaro (GLP-1/GIP), retatrutide targets three receptors to manage energy balance and metabolism.
GLP-1 (Glucagon-like peptide-1): Reduces appetite and slows stomach emptying, increasing satiety.
GIP (Gastric inhibitory polypeptide): Enhances fat metabolism and improves insulin response.
Glucagon (GCG): Increases energy expenditure (calorie burning).
Key Metabolic Effects:
Appetite Suppression: It significantly lowers food cravings and hunger.
Increased Metabolism: By activating the glucagon receptor, it forces the body to burn more energy, even at rest.
Fat Reduction: It promotes the breakdown of stored fat rather than just suppressing hunger.
Results & Administration: Administered as a weekly injection, clinical trials (Phase 2) showed participants losing up to 24% of their body weight after 48 weeks. It is currently in Phase 3 trials and is designed to improve glycemic control and reduce fat.
Retatrutide is often considered a "metabolic reset" because it addresses both energy intake (appetite) and output (metabolism) simultaneously.
When will I see results?
In clinical trials, Retatrutide results follow a progressive timeline, with internal biological changes starting almost immediately, while physical will take a few weeks to show.
Timeline of Expected Results
Hours to Days 1–3: Initial appetite suppression usually begins within 24 to 72 hours of the first injection. Participants often report a "silent snack zone" where the impulse to graze or cravings for sweets noticeably decrease.
Weeks 1–4: Early weight loss is typically 2% to 5% of body weight, largely due to reduced portion sizes and initial water weight loss. You may start feeling full sooner during meals.
Weeks 8–12: Measurable physical changes often emerge. You may notice clothing fitting looser and a reduction in facial puffiness. In trials, participants often reached 5% to 10% weight loss by this stage.
Months 6–12: This is the "significant transformation phase". In Phase 2 trials, participants on the highest dose achieved an average weight reduction of 17.5% at 24 weeks and reached 24.2% by 48 weeks.
Month 12–16: Peak results are typically seen by week 48 to 68. Long-term Phase 3 data (TRIUMPH-4) reported average losses as high as 28.7% (roughly 71 lbs) over 68 weeks for those on the highest doses.
Metabolic & Health Marker Results
Beyond weight loss, Retatrutide shows rapid impact on other health markers:
Blood Sugar: Significant drops in HbA1c (1.3 to 2.0 percentage points) occur as early as 24 weeks, with many participants achieving normoglycemia.
Liver Fat: In specialized studies, some participants saw an 80%+ reduction in liver fat by week 24.
Joint Pain: Improvements in mobility and relief from osteoarthritis-related knee pain are common milestones between months 9 and 16.
Note: Because Retatrutide is a research peptide in Phase 3 trials, these results are based on clinical study averages and may vary depending on individual biology, dose escalation, and lifestyle. You may purchase Retartrutide as a researcher.
Want Muscle? Explore Options
Get the Latest Health Updates For Yourself
Text "GOALS" to 725-433-1444 or call for quickest response. We are dedicated to help you thrive.